File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Book Chapter: In the Pipeline: Emerging Therapy for MDS and MDS/MPN

TitleIn the Pipeline: Emerging Therapy for MDS and MDS/MPN
Authors
Gill, HarinderLee, EmilyMo, Pinky
Issue Date28-Sep-2023
PublisherSpringer Nature Singapore
Abstract

Novel agents in combination with hypomethylating agents are an emerging strategy for clinical trials in involving higher-risk MDS or MDS/MPN and in patients harbouring high-risk mutations such as those involving TP53. In this chapter, we highlight the important pathogenetic pathways in MDS and MDS/MPN and their targeting.


Persistent Identifierhttp://hdl.handle.net/10722/341852
ISBN
9789819938094

 

DC FieldValueLanguage
dc.contributor.authorGill, Harinder-
dc.contributor.authorLee, Emily-
dc.contributor.authorMo, Pinky -
dc.date.accessioned2024-03-26T05:37:41Z-
dc.date.available2024-03-26T05:37:41Z-
dc.date.issued2023-09-28-
dc.identifier.isbn9789819938094-
dc.identifier.urihttp://hdl.handle.net/10722/341852-
dc.description.abstract<p>Novel agents in combination with hypomethylating agents are an emerging strategy for clinical trials in involving higher-risk MDS or MDS/MPN and in patients harbouring high-risk mutations such as those involving <em>TP53</em>. In this chapter, we highlight the important pathogenetic pathways in MDS and MDS/MPN and their targeting.<br></p>-
dc.languageeng-
dc.publisherSpringer Nature Singapore-
dc.relation.ispartofPathogenesis and Treatment of Leukemia-
dc.titleIn the Pipeline: Emerging Therapy for MDS and MDS/MPN-
dc.typeBook_Chapter-
dc.identifier.doi10.1007/978-981-99-3810-0_35-
dc.identifier.eisbn9789819938100-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats